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returned the study survey. The SF-36 instrument was used to measure HRQOL and
comparedwith the provincial norm. The secondwavewas a random sample of 323
respondents from the initial 1617 first-wave respondents, who were interviewed
with an identical instrument 3 years after the earthquake. ANOVA and t-tests were
used to compare SF-36 scores among residents by earthquake impact levels;
against a provincial norm; and between 8months and 3 years. RESULTS: The SF-36
subscale scores differed by the impact level of earthquake except for RP. Compared
with the Sichuan provincial norm, all subscale SF-36 scores of the first-wave re-
spondents were lower atmonth 8 (all p-values0.001). Seven subscale scores of RP,
BP, GH, VT, SF, RE, and MH at 3 years were statistically lower than the provincial
norm (all p-values0.05). Among the second-wave respondents, all the 3-year
SF-36 subscale scores improved in comparison to those taken 8 months after the
earthquake except for RP and SF. CONCLUSIONS: The HRQOL declined compared
with the norm, especially the psychological aspects. Furthermore, the HRQOL 3
years after the earthquake were persistently lower than the norm level, despite its
recovery from 8-month level.
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OBJECTIVES: In adults with executive dysfunction and mild major depressive dis-
order (MDD), lisdexamfetamine dimesylate (LDX) augmentation significantly im-
proved executive dysfunction (primary endpoint) on the Behavior Rating Inventory
of Executive Function–Adult Version (BRIEF-A). Because cognitive impairment can
affect functioning, including the ability to work, we describe LDX effects on func-
tional outcomes from the aforementioned study. METHODS: This double-blind,
placebo-controlled study enrolled participants (18–55 y)withmildMDD (Montgom-
ery-Åsberg Depression Rating Scale total score 18) and executive dysfunction
(BRIEF-A Global Executive Composite T-score60) on stable SSRI monotherapy for
8 weeks. After 2 weeks of screening, participants were randomized to 9 weeks of
double-blind LDX (week 1: 20 mg/d; weeks 2–6: maintain or increase LDX in 10-mg
increments weekly to 70 mg/d; weeks 7–9: maintain optimized dose) or placebo
augmentation, followed by 2 weeks of single-blind placebo. Prespecified secondary
functional endpoints included theQuality of Life Enjoyment and SatisfactionQues-
tionnaire (Q-LES-Q) and Endicott Work Productivity Scale (EWPS). Analyses in-
cluded analysis of covariance in randomized participants who took 1 study drug
dose and had 1 postbaseline BRIEF-A assessment. RESULTS: Of 143 randomized
participants (placebo, 72; LDX, 71), 119 completed double-blind treatment (placebo,
59; LDX, 60). For the Q-LES-Q, least squares (LS) mean (95% CI) treatment differ-
ences at endpoint significantly favored LDX in 5 of 10 domains: “physical health
activities” (9.6 [3.6, 15.6]; p0.0020), “feelings” (5.8 [0.0, 11.6]; p0.0481), “work” (9.1
[2.0, 16.1]; p0.0123), “household duties” (8.8 [2.2, 15.4]; p0.0094), and “general
activities” (6.2 [1.0, 11.4]; p0.0191); no differentiation was observed in the other
domains. For the EWPS, the LS mean (95% CI) treatment difference at endpoint
numerically favored LDX but was not statistically significant (–4.4 [–10.9, 2.0;
p0.1731). CONCLUSIONS: These findings suggest LDX augmentation modestly
improves functional outcomes in adults with partially or fully remitted MDD.
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OBJECTIVES: Schizophrenic patients often remain symptomaticwith predominant
(or persistent) negative symptoms (PNS) despite receiving antipsychotic therapy.
Negative symptoms might include social withdrawal, poverty of speech, apathy,
inability to experience pleasure, limited emotional expression, or defects in atten-
tion control. Several definitions of PNS exist. The purpose of this study is to de-
scribe PNS population according to several definitions. METHODS: Definitions of
patients with PNS were searched in literature, and applied to patients from the
EuroSC cohort (N288 in France, N618 in Germany andN302 in UK). Five assess-
ments including Positive and Negative Symptoms Scale (PANSS) were performed
over 2 years. The extent of overlap between definitions was assessed at baseline,
and pathways of patients with PNS were explored over 2 years. Bivariate analyses
were conducted to compare patients with PNS to others in terms of quality of life
(QoL), side effects, functioning and depression. RESULTS: Six definitions were
found, all based on PANSS subscores. Results differed according to countries, with
an average of 41% of patients with PNS in France, 24% in UK and 13% in Germany.
For all definitions, about 60% of patients with PNS at baseline still had PNS after 6
months, and about 40% still had PNS after 2 years. PNS patients were found to have
a lower QoL (EQ-5D: 0.70 vs. 0.74 on average), more severe side-effects (SAS: 4.2
vs.3.2 on average), lower functioning (GAF: 40 vs. 54 on average) and to be more
depressed (CDSS: 3.7 vs.2.6 on average). CONCLUSIONS: Our study suggests that
patients with PNS form a stable population overtime with higher clinical burden.
The lack of specific treatment pattern raises the issue of the need for specific
disease management strategy of patients with PNS. Further analyses on clinical
and economical burden of these patients are required.
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OBJECTIVES: Anxiety disorders represent the most common psychiatric illness in
the US Pharmacotherapy is the most common approach to treat anxiety disorders.
Our objective is to determine the extent to which patients with anxiety disorder
seek pharmacological treatment and to examine factors that are associated with
the pharmacological treatment utilization. METHODS: We evaluated Medical Ex-
penditures Panel Survey (MEPS) data (data pooled for survey calendar years 2005-
2009). Adult MEPS respondents (age17), identified as having anxiety disorder con-
dition (n  3412) were included in the study. Andersen behavioral model of health
services utilization was used as the conceptual framework for the study. Depen-
dent variables were defined as utilization of anti-anxiety medications (model A)
and number of prescriptions for anxiety disorders (model B). Independent vari-
ables, i.e. predisposing, enabling and need variables, were defined for each model
based on current literature and availability in MEPS. Logistic regression (model A)
and Poisson regression (model B) analyses were conducted to find the predictors of
medication utilization as well as the number of prescriptions. RESULTS: Sixty-one
percent of adults with anxiety disorder take anti-anxiety medication (95% CI: 59%,
63%). Formodel A, significant variables were race (Native Hawaiian/Pacific Islander
versus white, OR0.001, p0.001), education (no education versus elementary
school, OR 0.295, p0.039), prescription drug insurance coverage (no coverage
versus coverage for at least one round in year, OR 0.768, p 0.005), insurance
coverage (private insurance versus public insurance, OR 0.749, p 0.034), having
irritable bowel syndrome (IBS) (OR2.951, p0.016), andmood disorder (OR2.194,
p0.0001). For model B, significant variables were cost index (-0.391, p0.0001),
number of comorbidities (0.163, p0.0001) and age (-0.174, p 0.043).
CONCLUSIONS: Utilization rate of anti-anxiety medications among adult patients
with anxiety disorder is high. Demographic variables are less likely to affect this
utilization, while enabling and clinical need variables are highly influential.
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OBJECTIVES: To compare deviation rates from the labeled average daily consump-
tion (DACON) in patients with ADHD initiated on lisdexamfetamine dimesylate
(LDX) versus other once-daily FDA-approved stimulant medications. METHODS:
Patients with ADHD initiated on a stimulant medication on or after February 23,
2007 were selected from a large US claims database. Based on age and previous
treatment, patientswere classified into treatment-naïve or previously-treated chil-
dren/adolescents (6-17 years old), and adults (18 years old), respectively. Further-
more, based on the initiated medication, patients were classified into 4 cohorts:
LDX, methylphenidate HCl (OROS MPH), other methylphenidate/dexmethylpheni-
date HCl long acting (MPH LA), and amphetamine long acting (AMPH LA). DACON
was defined as the quantity of units supplied divided by the number of days of
supply in the 12-month study period. The proportion of patientswhodeviated from
the labeledDACON (ie, DACON1 pill/day) and the likelihood of deviation from the
labeled DACONwere compared across cohorts using chi-square tests andmultiple
logistic regression models, respectively. RESULTS: Across all subgroups, the pro-
portion of patients who deviated from the labeled DACONwas significantly higher
in each treatment cohort (range: 7.4%-29.4%) versus the LDX cohort (range: 2.9%-
9.9%) (all p0.001). After adjustments, uniformly across all subgroups, patients in
each treatment cohort were significantly more likely to deviate from the labeled
DACON versus LDX-treated patients. In children/adolescent groups, odds ratios
ranged from 2.6 to 3.7 and 2.9 to 4.1 in the previously-treated and the treatment-
naïve cohorts, respectively (all p0.001). In adult groups, odds ratios ranged from
2.1 to 4.0 and 2.1 to 4.1 in the previously-treated and the treatment-naïve cohorts,
respectively (all p0.001). CONCLUSIONS: Findings suggest that LDX-treated pa-
tients were more likely to adhere to the dosing regimen recommended in FDA
labels and were less likely to have a DACON 1 compared with patients treated
with other once-daily stimulant ADHD medications.
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OBJECTIVES: Significant increase in antidepressant use has been described over
the last two decades. To date, no study has compared trends in antidepressant use
in countries with different economic characteristics. TheOBJECTIVES were to de-
scribe and compare the growth of antidepressants use by pharmacologic class from
the late 1990s onward among 10 countries and the relation to the evolution of the
Gross Domestic Product (GDP), total health expenditures (HE) and the pharmaceu-
tical expenditures (PE) in each country.METHODS: Retrospective analysis of sales
data extracted from IMSHealth commercial database between 1999 and 2008 in US,
France, Germany, UK, Spain, Italy, Greece, Poland, Hungary and the Czech Repub-
lic. Description of antidepressant volume in Defined Daily Dose (DDD) per capita,
comparison of growth (% change between 1999 and 2008) and descriptive relation-
ship with % change in GPD, PE and HE. RESULTS: Antidepressant use increased
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from an average of 7.8 to 16.4 DDD/capita between 1999 and 2008. Three groups of
countries were identified: high, medium and low use of antidepressants countries.
Overall, antidepressant growth was observed (41% to 325% range) and was more
pronounced in low-use countries. By 2008, SSRIs were the predominant class in all
countries; followed by SNRIs whereas TCAs consumption went down. Over the
studied period, GDP and HE growth were aligned across countries; PE growth was
associated with antidepressant expenditures. CONCLUSIONS: Countries with
lower GDP / capita (and higher GDP growth) and lower baseline antidepressant
volumes are heading in the same direction as the higher income countries did in
the past, recording a 200-300% volume growth between 1999 and 2008). This offers
a unique opportunity tomonitor the anticipated health outcomes of their prescrip-
tion, which were missed in the past and which are valuable for future mental
health policy.
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OBJECTIVES: Sleep deprivation and disturbances can result in lowered productiv-
ity and increased errors/accidents. Existing research has documented higher use of
sleepmediations amongwomen; however, little is known about other factors such
as race, ethnicity and its association with the use of sleepmedications in a nation-
ally representative study sample. The objective of this study was to investigate the
relationship of various factors such as race, ethnicity, gender, employment status
with the use of sleepmedications in the US population.METHODS:A retrospective,
cross-sectional study design was used. Data from the 2009 Medical Expenditure
Panel Survey, a nationally representative survey of US population, were used for
this analysis. The study population included all survey respondents over the age of
18. A multiple logistic regression model was built to analyze odds of reporting use
of prescription or non prescription sleep medication. RESULTS: Of the total 20568
survey respondents, 8.28% (n 1703) used some type of medication to fall asleep in
the year 2009. The odds of reporting use of sleep medication were significantly
higher among females (OR1.404 CI 1.254-1.571) compared to males. The odds of
sleepmedication use were significantly lower among African American (OR 0.529
CI 0.453-0.617), Asian American (OR 0.387 CI 0.283-0.530) and Hispanic (OR 0.717
CI 0.621- 0.828) women compared to Non Hispanic Caucasian women. Unemploy-
ment (OR1.909 CI 1.674-2.178) and depression (OR5.009 CI 4.446-5.643) were
highly correlated with use of sleep medications. Additionally, compared to lower
income levels, higher income levels had lower odds of sleep medication use.
CONCLUSIONS: Unemployed Non-Hispanic Caucasian women in low income
households are more likely to use prescription or non prescription sleep medica-
tions. Further research on why such differences exist is necessary. The factors
identified in this study should be further investigated to identify vulnerable popu-
lations to investigate underlying causes of sleep disorders.
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OBJECTIVES: To evaluate daily average consumption (DACON) and average daily
costs (ADC) of duloxetine for patients with various pain and mood conditions sub-
sequent to the recent FDA approval of duloxetine in the management of chronic
musculoskeletal pain.METHODS: Retrospective analysis of commercially insured
patients prescribed duloxetine between January 1, 2011 and September 30, 2011
using the IMS Longitudinal Prescription and Medical Claims Database. This analy-
sis focused on patients diagnosed with only one of the following: chronic lower
back pain (CLBP), osteoarthritis (OA), fibromyalgia (FM), diabetic peripheral neuro-
pathic pain (DPNP), major depressive disorder (MDD), and generalized anxiety dis-
order (GAD). Patients were assigned to study cohorts based on ICD-9 codes re-
corded within -180/07 days of the date of the first duloxetine prescription filled
during the study interval. DACONs were defined as weighted averages of the total
number of pills dispensed by total days of supply across pill strength for all patients
within each cohort. DACONs were converted to ADCs using January 2011 average
wholesale prices (AWP). A second analysis based on prescriptions between January
1, 2010 and September 30, 2010 was conducted for comparative purposes.
RESULTS: A total of 553,253 duloxetine patients were included in the analysis.
DACONswere 1.27 (for CLBP, 1.26 for OA, 1.28 for FM, and 1.27 for DPNP, versus 1.44
for MDD (p0.0001 for each of the four pain conditions) and 1.32 for GAD. The
resultingADCs for the four pain conditions varied only slightly, from$6.99 for OA to
$7.13 for FM. ADC for MDD was notably higher ($8.00). The overall DACON for 2011
represented amodest decline from 2010,most notably for CLBP and FM (to 1.35 and
1.33, respectively; p0.0001 for both). CONCLUSIONS: 2011 DACONs and ADCs
varied little across the four chronic pain conditions for which duloxetine has been
approved for use by the FDA, all of which were significantly lower than for MDD.
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OBJECTIVES: To determine the association between depression treatment and
short-term health care expenditures using a nationally representative sample of
Medicare beneficiaries with chronic physical illnesses and depression.METHODS:
We employed a longitudinal design and used data from 2000 through 2005 of the
Medicare Current Beneficiary Survey, a nationally representative survey of Medi-
care benefi ciaries. Two years of observation, yielding five cohorts were used to
measure depression treatment in the baseline year andhealth care expenditures in
the second. The bivariate relationship between depression treatment in baseline
year and health care expenditures in the follow-up year was tested with t-tests.
Ordinary least squares (OLS) regressions on logged dollars were used to assess the
relationship between depression treatment and health care expenditures after
controlling for demographic, socio-economic, health status, and lifestyle risk
factors. RESULTS: Compared to no depression treatment ($16,795), the average
total expenditures were higher for those who used antidepressants only ($17,425)
and those who used psychotherapy with or without antidepressants ($19,733).
After controlling for the independent variables, antidepressant use and psycho-
therapy with or without antidepressants were associated with 21% and 31% in-
crease in total expenditures, respectively. For each expenditure type except for the
other category, we observed a statistically significant relationship between depres-
sion treatment and expenditures. CONCLUSIONS: Among the elderly with chronic
physical illnesses, depression treatment was associated with greater short-term
health care expenditures. Future research needs to examine whether this relation-
ship remains over a longer period of time.
PMH70
MEDICATION ADHERENCE AND PERSISTENCE IN PATIENTS TREATED WITH
DULOXETINE
Able S, Cui Z, Shen W
Eli Lilly and Company, Inc., Indianapolis, IN, USA
OBJECTIVES: The purpose of this studywas to compare adherence and persistence
for patients treated with duloxetine across several diagnoses categories: major
depressive disorder (MDD), fibromyalgia (FM), osteoarthritis (OA), and chronic
lower back pain (CLBP). METHODS: Patients age 18-64 initiating duloxetine treat-
ment during 2008 were identified in the Thomson Reuters MarketScan® Database.
The index event was defined as the first duloxetine prescription filled during the
study period with no duloxetine coverage during the previous 90 days. Patients
were assigned to disease-category cohorts on the basis of ICD-9 codes recorded on
medical claims dated within 1/- 3 month of the initial duloxetine prescription.
Adherence was measured over both 365- and 90-day post duloxetine initiation
periods as the percent of patients with a medication possession ratio 0.8. Persis-
tencewasmeasured over a 365-day post-initiation period as the percent of patients
with length of therapy  180 days. 2-tests were used to compare differences in
adherence and persistence across patient cohort. RESULTS: A total of 18,406 pa-
tients with one of the 4 identified diagnosis categories were identified as initiating
duloxetine in 2008: MDD (8,334), FM (3,630), OA (1,458) or CLBP (4,984). Adherence
was directionally greater among patientswithMDD (37.3%) versus FM (35.3%) or OA
(35.7%), and statistically significantly greater than CLBP (29.9%; p0.005). Compar-
isons of 90-day adherences were similar, with MDD (58.8%) directionally higher
than FM (54.1%) or OA (57.8%), and statistically significantly greater than CLBP
(50.0%; p0.005). Comparisons of persistencewere similar to adherence. For exam-
ple, persistence was 47.5% for MDD versus 38.7% for CLBP (p0.005).
CONCLUSIONS: Duloxetine adherence and persistence were similar among pa-
tients with MDD, FM, and OA, and significantly less among those with CLBP. These
relationships were consistent across variations in technical assumptions em-
ployed in calculating the study measures.
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OBJECTIVES: The study examined antidepressant utilization patterns and expen-
ditures in older adults in United States (US). METHODS: The study involved anal-
ysis of household and prescription files of the 2009 Medical Expenditure Panel
Survey (MEPS) data. The study sample included all older adults ( 50 years) with
depression. The analysis focused on antidepressant classes, namely selective se-
rotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), serotonin-
norepinephrine reuptake inhibitors (SNRIs), Monoamine Oxidase Inhibitors (MAO),
phenylpiperazine and tetracyclics. Descriptive weighted analysis was performed
to examine antidepressant use patterns and prescription expenditures in commu-
nity dwelling depressed older adults. RESULTS: According to the 2009 MEPS, 11.36
million older adults were diagnosed with depression for an overall prevalence of
11.50% (95% CI, 12.34- 47.50). Most older adults with depression were 50-64 years of
age (66.79%), female (67.25%), and white (89.85%). Antidepressants were used by
78.61% (95% CI, 75.79- 81.43) of older adults with depression. The most prescribed
class of antidepressants was SSRIs (54.86%), followed by SNRIs (18.49%), phe-
nylpiperazine (7.92%), TCAs (6.96%) and tetracyclics (3.19%). Total antidepressant
prescriptionexpenditureswere $9.5 billion (95%CI, 8.3-10.7 billion).Highexpenditures
were found for SNRI ($4.3 billion, or 44.62% of antidepressant expenditures), followed
by SSRI ($3.5 billion, or 37.60%)), TCA ($172 million, or 1.8%), and phenylpiperazine
($131 million, or 1.37%). The average prescription price was also highest for SNRI
($181.56), followed by SSRI ($49.22), tetracyclic ($28.17), TCA ($19.13), and phe-
nylpiperazine ($13.64). CONCLUSIONS: Depression is highly prevalent among older
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